Research
Hormonal
Immediate-release melatonin at moderate doses effectively reduces sleep onset latency and improves symptoms associated with poorly coupled circadian rhythms, such as seasonal affective and bipolar disorders.
If you struggle with falling asleep or have seasonal mood shifts, immediate-release melatonin at a moderate dose is a valid, evidence-backed option. It works by signaling your brain that it is night, helping to reset your internal clock and initiate sleep.
GoodSupportsHIGH confidence
Melatonin immediate release is already effective, at moderate doses, for reducing difficulties of falling asleep or improving symptoms associated with poorly coupled circadian rhythms, including seasonal affective and bipolar disorders.
Why this rating
The paper is a comprehensive review citing numerous studies, though it notes variability in individual response.
Source
Neurobiology, Pathophysiology, and Treatment of Melatonin Deficiency and Dysfunction
Rüdiger Hardeland · The Scientific World JOURNAL · 2012
DOI 10.1100/2012/640389
narrative_reviewCited 170×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Prolonged-release melatonin or synthetic agonists are required for replacement therapy aimed at maintaining sleep throughout the night, as immediate-release formulations are insufficient for sleep maintenance.Good
- Melatonin deficiency or dysfunction is associated with a wide range of diseases beyond sleep disorders, including dementia, mood disorders, cancer, diabetes type 2, and severe pain.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →